# Khellin

**Cat. No.:** HY-B1394

**CAS No.:** 82-02-0

**Molecular Formula:** $C_{14}H_{12}O_5$

**Molecular Weight:** 260.24

**Target:** EGFR

**Pathway:** JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

**Storage:** 4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 16.67 mg/mL (64.06 mM; ultrasonic and warming and heat to 60°C)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 3.8426 mL | 19.2130 mL | 38.4261 mL |
| | 5 mM | 0.7685 mL | 3.8426 mL | 7.6852 mL |
| | 10 mM | 0.3843 mL | 1.9213 mL | 3.8426 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an EGFR inhibitor with an $IC_{50}$ of 0.15 μM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects[1][2].

**$IC_{50}$ & Target**

IC50: 0.15 μM (EGFR)[1]

**In Vitro**

Khelline exhibits anti-proliferative activity for MCF-7 cells and Hela cells[1].

Khellin inhibits the pathways of $Ca^{2+}$ influx which are activated by both noradrenaline and high $K^+$[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Abdel-Sattar S Hamad Elgazwy, et al. Molecular modeling study bioactive natural product of khellin analogues as a novel potential pharmacophore of EGFR inhibitors. J Enzyme Inhib Med Chem. 2013 Dec;28(6):1171-81.

[2]. A Ubeda, et al. Relaxant actions of khellin on vascular smooth muscle. J Pharm Pharmacol . 1989 Apr;41(4):236-41.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA